盐酸绿卡色林(Lorcaserin Hydrochloride) - 药物靶点：5-HT2C receptor_在研适应症：癫痫性脑病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Lorcaserin、Lorcaserin Hydrochloride Hemihydrate、Lorcaserin hydrochloride (USAN)

+ [6]

靶点

5-HT2C receptor

作用机制

5-HT2C receptor激动剂(5-羟色胺2C受体激动剂)

治疗领域

神经系统疾病

在研适应症

癫痫性脑病

非在研适应症

2型糖尿病药物滥用Dravet综合征+ [4]

原研机构

Arena Pharmaceuticals, Inc.

在研机构

Harmony Biosciences LLC

非在研机构

Arena Pharmaceuticals, Inc.

Eisai, Inc.

Epygenix Therapeutics, Inc.初创企业

+ [1]

最高研发阶段临床前

首次获批日期

美国 (2012-06-27),

肥胖

最高研发阶段(中国)-

特殊审评罕见儿科疾病 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构

分子式C11H14ClN

InChIKeyXTTZERNUQAFMOF-QMMMGPOBSA-N

CAS号616202-92-7

查看全部结构式(2)

关联

54

项与盐酸绿卡色林相关的临床试验

NCT04205071 / Withdrawn临床1期IIT

Pilot Trial of Acute Effect of Lorcaserin to Reduce Patient-Reported Symptoms of Taxane- and Oxaliplatin-Induced Peripheral Neuropathy

This phase I trial studies how well lorcaserin works in treating chemotherapy-induced peripheral neuropathy in patients with stage I-IV gastrointestinal or breast cancer. Chemotherapy-induced peripheral neuropathy is a nerve problem that causes pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. This condition can occur in patients who have received taxane chemotherapy drugs, or the chemotherapy drug oxaliplatin. Lorcaserin may improve chemotherapy-induced peripheral neuropathy by reducing pain, preventing or relieving joint symptoms, and improving balance.

开始日期2020-11-01

申办/合作机构

Ohio State University Comprehensive Cancer Center

[+1]

NCT04572243 / Terminated临床3期

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of Lorcaserin as Adjunctive Treatment in Subjects With Dravet Syndrome

The primary purpose of the study is to demonstrate that lorcaserin has superior efficacy compared to placebo on percent change in frequency of convulsive seizures per 28 days in participants with Dravet syndrome.

开始日期2020-09-23

申办/合作机构

Eisai, Inc.

NCT04396847 / Terminated临床2期IIT

Human Laboratory Screening of Lorcaserin in Smokers With Alcohol Use Disorder

Heavy-drinking smokers, including those with alcohol use disorder (AUD), are at increased risk for numerous negative health outcomes relative to those who use alcohol or cigarettes only. Although heavy-drinking smokers are recognized as an important subgroup for clinical and public health interventions, there are presently no approved medications for the joint indication of alcohol reduction and smoking cessation. Based on evidence that the serotonin system plays a role in alcohol and nicotine consumption and relapse, this study aims to examine whether a serotonin medication alters alcohol and nicotine responses in smokers with AUD, informing its potential utility as a candidate therapy for this clinical subgroup.

开始日期2019-10-25

申办/合作机构

The Mind Research Network

100 项与盐酸绿卡色林相关的临床结果

登录后查看更多信息

100 项与盐酸绿卡色林相关的转化医学

登录后查看更多信息

100 项与盐酸绿卡色林相关的专利（医药）

登录后查看更多信息

451

项与盐酸绿卡色林相关的文献（医药）

2024-12-01·Neuropharmacology

Activation of ventral pallidum-projecting neurons in the nucleus accumbens via 5-HT2C receptor stimulation regulates motivation for wheel running in male mice

Article

作者: Nishitani, Naoya ; Futami, Yusaku ; Kaneda, Katsuyuki ; Deyama, Satoshi ; Nishida, Ryoma ; Niitani, Kazuhei

Rodents have a strong motivation for wheel running; however, the neural mechanisms that regulate their motivation remain unknown. We investigated the possible involvement of serotonin (5-HT) systems in regulating motivation for wheel running in male mice. Systemic administration of a 5-HT_1A receptor antagonist (WAY100635) increased the number of wheel rotations, whereas administration of a 5-HT_2A or 5-HT_2C receptor antagonist (volinanserin or SB242084, respectively) decreased it. In the open field test, neither WAY100635 nor volinanserin affected locomotor activity, whereas SB242084 increased locomotor activity. To identify the brain regions on which these antagonists act, we locally injected these into the motivational circuitry, including the nucleus accumbens (NAc), dorsomedial striatum (DM-Str), and medial prefrontal cortex (mPFC). Injection of SB242084 into the NAc, but not the DM-Str or mPFC, reduced the number of wheel rotations without altering locomotor activity. The local administration of WAY100635 or volinanserin to these brain regions did not affect the number of wheel rotations. Immunohistochemical analyses revealed that wheel running increased the number of c-Fos-positive cells in the NAc medial shell (NAc-MS), which was reduced by systemic SB242084 administration. In vitro slice whole-cell recordings showed that bath application of the 5-HT_2C receptor agonist lorcaserin increased the frequency of spontaneous excitatory and inhibitory postsynaptic currents in the ventral tegmental area (VTA)-projecting neurons, whereas it only increased the frequency of spontaneous excitatory postsynaptic currents in ventral pallidum (VP)-projecting neurons in the NAc-MS. These findings suggest that the activation of VP-projecting NAc-MS neurons via 5-HT_2C receptor stimulation regulates motivation for wheel running.

2024-12-01·Regulatory Toxicology and Pharmacology

Mutagenicity and genotoxicity evaluation of 15 nitrosamine drug substance-related impurities in human TK6 cells

Article

作者: McGovern, Timothy J. ; Davis-Bruno, Karen L. ; Heflich, Robert H. ; Davis-Bruno, Karen L ; McGovern, Timothy J ; Keire, David A. ; King, Sruthi T. ; Atrakchi, Aisar H ; Dorsam, Robert T. ; Guo, Xiaoqing ; Li, Xilin ; Dorsam, Robert T ; Heflich, Robert H ; Mei, Nan ; Keire, David A ; King, Sruthi T ; Atrakchi, Aisar H. ; Le, Yuan

Nitrosamine drug substance-related impurities (NDSRIs) are a sub-category of N-nitrosamine drug impurities that share structural similarity to the corresponding active pharmaceutical ingredient. The mutagenicity of NDSRIs is poorly understood. We previously tested a series of NDSRIs using the Enhanced Ames Test (EAT). In this follow-up study, we further examined the genotoxicity and mutagenicity of 15 of these NDSRIs in human TK6 cells. Seven EAT-positive NDSRIs, including N-nitroso-nortriptyline, N-nitroso-fluoxetine, N-nitroso-desmethyl-diphenhydramine, N-nitroso-duloxetine, N-nitroso-lorcaserin, N-nitroso-varenicline, and N-nitroso-sertraline, induced concentration-dependent increases in micronuclei after bioactivation with hamster liver S9. These NDSRIs were also mutagenic in the TK and HPRT gene mutation assays, consistent with their positive EAT results. In the presence of hamster liver S9, the eight EAT-negative NDSRIs were negative in the micronucleus assay and negative for mutation induction. Using TK6 cells endogenously expressing a single human cytochrome P450 (CYP), we found that CYP2C19, CYP2B6, CYP2A6, and CYP3A4 are key enzymes activating the genotoxicity and mutagenicity of these NDSRIs. Overall, the hamster S9-mediated TK6 cell mutagenicity results agreed with those observed in the EAT, indicating consistency in the mutagenic responses produced by NDSRIs across different testing systems. These data support the use of EAT for hazard identification and safety assessment of NDSRIs.

2024-10-01·Epilepsia

Utilizing an acute hyperthermia‐induced seizure test and pharmacokinetic studies to establish optimal dosing regimens in a mouse model of Dravet syndrome

Article

作者: Rower, Joseph E. ; Reilly, Christopher A. ; Wilcox, Karen S. ; Johnson, Kristina ; Metcalf, Cameron S. ; Mensah, Jeffrey A. ; Freeman, Tia

AbstractObjectiveThe current standard of care for Dravet syndrome (DS) includes polytherapy after inadequate seizure control with one or more monotherapy approaches. Treatment guidelines are often based on expert opinions, and finding an optimal balance between seizure control and adverse drug effects can be challenging. This study utilizes the efficacy and pharmacokinetic assessment of a second‐line treatment regimen that combines clobazam and sodium valproate with an add‐on drug as a proof‐of‐principle approach to establish an effective therapeutic regimen in a DS mouse model.MethodsWe evaluated the efficacy of add‐on therapies stiripentol, cannabidiol, lorcaserin, or fenfluramine added to clobazam and sodium valproate against hyperthermia‐induced seizures in Scn1aA1783V/WT mice. Clobazam, N‐desmethyl clobazam (an active metabolite of clobazam), sodium valproate, stiripentol, and cannabidiol concentrations were quantified in plasma and brain using liquid chromatography–tandem mass spectrometry for the combinations deemed effective against hyperthermia‐induced seizures. The concentration data were used to calculate pharmacokinetic parameters via noncompartmental analysis in Phoenix WinNonLin.ResultsHigher doses of stiripentol or cannabidiol, in combination with clobazam and sodium valproate, were effective against hyperthermia‐induced seizures in Scn1aA1783V/WT mice. In Scn1aWT/WT mice, brain clobazam and N‐desmethyl clobazam concentrations were higher in the triple‐drug combinations than in the clobazam monotherapy. Stiripentol and cannabidiol brain concentrations were greater in the triple‐drug therapy than when given alone.SignificanceA polypharmacy strategy may be a practical preclinical approach to identifying efficacious compounds for DS. The drug–drug interactions between compounds used in this study may explain the potentiated efficacy of some polytherapies.

55

项与盐酸绿卡色林相关的新闻（医药）

2024-11-18

·药时代

一款减肥药撤市之后

正文共：2386字 1图预计阅读时间：5分钟由于患者招募困难，卫材终止了一项三期临床试验。美东时间2024年11月17日，知名行业媒体《Endpoints News》发文称，卫材终止了旗下Lorcaserin（氯卡色林）用于辅助治疗Dravet综合征的三期MOMENTUM 1研究（NCT04572243）。根据美国临床试验数据库（ClinicalTrials.gov）查询，目前MOMENTUM 1研究已处于终止状态，并提示该状态并非由于任何安全性或有效性原因导致。关于Dravet综合征 Dravet综合征（Dravet syndrome ，DS），为婴儿期起病的难治性癫痫综合征，由法国医生Charlotte Dravet在1978年首次报道，既往又称婴儿严重肌阵挛癫痫。 DS是一种罕见的癫痫性脑病，根据国外文献报道DS患病率为1/40000~1/20000（也有文献报道为发病率为1/15700~1/40900）占3岁以内婴幼儿癫痫的8%。2018年，该疾病被列入国家第一批罕见病目录（编号：105号）。 DS发病主要由遗传因素决定，其主要致病基因为钠离子通道α1亚单位基因SCN1A突变，此外如SCN1B、GABRG2等基因也可能与Dravet综合征有关。目前，DS暂无治愈方法，治疗主要是对症支持治疗，旨在减少癫痫发作的频率和强度。常用药物包括丙戊酸、司替戊醇、芬氟拉明、药用级大麻二酚、托吡酯等。其中，芬氟拉明作为一种5-HT2C受体激动剂，最早（1973年）被批准用于减肥，1997年因严重心脏毒性而停用。后来其较低剂量被重新启用，治疗一些癫痫性脑病：2020 年，美国和欧盟先后批准芬氟拉明作为DS治疗的添加药物。相同命运的氯卡色林此次，卫材终止的氯卡色林与芬氟拉明同为5-羟色胺（5-HT，又称血清素）受体激动剂。其研发历程也颇为相似。氯卡色林原研为Arena，2012年获FDA批准上市用于减肥治疗，商品名Belviq。后因市场表现一般，Arena于2017年将其权益卖给了卫材。值得一提的是，基于芬氟拉明的前车之鉴。FDA在批准Belviq时要求生产商开展一项随机、双盲、安慰剂对照的上市后研究，以评估氯卡色林的心血管风险。这项研究有12000例参与者，为期5年，于2018年6月结束。因此，氯卡色林是完成FDA要求的长期心脏安全研究的第一种新型减肥药物。只不过，FDA在对其安全性数据进行审查时发现，服用氯卡色林的患者被确诊为癌症的人数更多（462， 7.7% vs 423, 7.1%）。 2020年1月，FDA要求Belviq，Belviq XR从美国市场撤市。这对卫材而言，称得上无妄之灾。尽管癌症风险增高的原因还不明确，FDA也无法断定氯卡色林就是直接的致癌原因，但撤市已成定局。后者激流勇进，前者寸步难行芬氟拉明在肥胖症失利之后，在癫痫性脑病中“复活”。那么氯卡色林，理应也可走通这条路径。 2020年，卫材在与FDA协商后启动了氯卡色林治疗DS的三期MOMENTUM 1研究。当时目标是在美国招募58名受试者，如今4年过去，卫材还在招募在面临招募困境。根据《Endpoints News》报道，卫材一位的发言人通过电子邮件表示，“随着其他经FDA批准的疗法可用于治疗这一复杂的疾病（DS），招募患者进行试验性治疗变得极其困难。” 目前，针对DS的治疗涌现了各种新型治疗方式，包括但不限于：Stoke的反义寡核苷酸（ASO），STK-001；Longboard的5-HT2C受体超激动剂Bexicaserin；Encoded的AAV9介导的候选基因调控疗法，ETX101。其中，Bexicaserin已进入临床三期阶段。它虽然与氯卡色林、芬氟拉明同为5-HT2C受体激动剂，但却显示出对5-HT2C受体的选择性增加。具体而言，5-HT2受体次家族有A、B、C三种亚型，研究发现，中枢5-羟色胺主要通过作用于脑内5-羟色胺2C受体（5-HT2C）起到调节食欲的作用，这也是其减重的原因。而5-HT2A与5-HT2B激动，可能导致致幻活性与心脏毒性相关不良反应。芬氟拉明与右芬氟拉明的退市，便与同时激动5-HT2B导致的肺动脉高压和心脏瓣膜异常有关。至于氯卡色林，今年4月是我国列入第二类精神药品目录。此前（2013年），该药物已被FDA列入《管制物质法案》附表Ⅳ管理。以目前的科研水平结合当前商业价值，几经波折的氯卡色林，或许不值得继续投入资源。参考资料： 1.Eisai terminates Phase 3 trial of Dravet drug, citing recruitment challenges（Endpoints News） 2.clinicaltrials.gov 3.Dravet 综合征诊断与治疗的中国专家共识（癫痫杂志） 4.Wirrell E C, Laux L, Donner E, et al. Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel[J]. Pediatric Neurology,2017,68:18-34 5.田小娟，张月华. Dravet综合征治疗和预后研究进展[J]. 中国实用儿科杂志,2017(10):789-793 6.新列管药“氯卡色林”的由来（中国禁毒报） 7.其他公开资料封面图来源：pixabay 主管说没有预算，这个局怎么破？这里可以24小时免费观看FDA、EMA培训录像，自己不断成长，还不麻烦公司！~ 2024-11-17 第四届佛山创新药论坛圆满落幕，行业领袖共绘“BD出海与投融资”新未来 2024-11-16 FDA要变天！特朗普正式提名罗伯特·肯尼迪领导卫生与公众服务部 2024-11-15 版权声明/免责声明本文为原创文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢! 药时代官方网站:www.drugtimes.cn 联系方式: 电话:13651980212 微信:27674131 邮箱:contact@drugtimes.cn 点击查看更多精彩！

2024-11-18

·Firstwordpharma

Eisai officially winds down epilepsy programme

Eisai has shuttered a pair of clinical trials evaluating lorcaserin to treat Dravet syndrome after struggling to recruit enough patients with the rare form of epilepsy. The discontinuations, first disclosed in August by the Dravet Syndrome Foundation, affect the Phase III MOMENTUM 1 study and the MOMENTUM 2 extended access programme. "As other FDA-approved therapies have become available to treat this complex condition, recruiting patients for an investigational therapy has been exceedingly challenging," an Eisai spokesperson told FirstWord.The trials may have suffered from unfortunate timing, as they launched around the same time that a new drug with a similar mechanism of action hit shelves. Zogenix won FDA approval in 2020 for Fintepla (fenfluramine), a serotonin releasing agent, to treat Dravet syndrome; the drugmaker was then bought by UCB for $1.9 billion in 2022. According to the disease foundation's August release, "Just as the studies for lorcaserin began, many patients were trying the newly available Fintepla for the first time, which may have been a factor in the difficulties enrolling enough participants in the study."Earlier this year, FirstWord spoke with a dozen key opinion leaders (KOLs) about the treatment landscape for epilepsy, and several physicians thought lorcaserin could offer a better safety profile than Fintepla given its more precise mode of action as a selective serotonin 2C receptor agonist (see – Spotlight On: Emerging epilepsy drugs to watch).It's the second major setback for lorcaserin across its decades-long development history. Approved by the FDA as Belviq in 2012 as a weight-loss aid, lorcaserin was withdrawn from markets in 2020 due to an increased occurrence of cancer.

上市批准并购临床3期

2024-11-17

·Endpoints

Eisai terminates Phase 3 trial of Dravet drug, citing recruitment challenges

Eisai has stopped the Phase 3 clinical development of an adjunctive treatment for Dravet syndrome, a spokesperson confirmed to Endpoints News on Friday afternoon. The Tokyo drugmaker terminated the late-stage trial of lorcaserin this week, according to an update to the federal clinical trials database. The medicine, which has FDA orphan drug designation, was still listed on Eisai’s public pipeline as of Nov. 8. Dravet, a rare disorder, leads to epilepsy and affects people starting in infancy. “As other FDA-approved therapies have become available to treat this complex condition, recruiting patients for an investigational therapy has been exceedingly challenging,” the Eisai spokesperson said in an email. They said the decision wasn’t related to safety issues. Eisai got the oral drug from Arena Pharmaceuticals and marketed it as Belviq for obesity. But in 2020, the FDA requested that Eisai pull the drug after concerns about cancer outweighed its benefits. The drug is a 5-HT2C agonist that selectively activates serotonin 2C receptors in the brain. The goal is to suppress seizures in patients with Dravet syndrome. Another drugmaker developing a 5-HT2C superagonist, Longboard Pharmaceuticals, entered Phase 3 in Dravet patients this fall. Lundbeck is buying Longboard for $2.6 billion in cash. Bright Minds Biosciences is also developing a related drug and is in mid-stage testing in rare epilepsies, with preclinical work in obesity, as well. Stoke Therapeutics, Jazz Pharmaceuticals and other companies are also working in Dravet. Takeda’s drug failed a Phase 3 this summer.

临床3期孤儿药

100 项与盐酸绿卡色林相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06613	盐酸绿卡色林	A08AA11	DB04871

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
Dravet综合征	临床1期	加拿大	Eisai, Inc.	2020-09-23
癫痫性脑病	临床前	美国	Harmony Biosciences LLC	2024-11-01
Lennox-Gastaut综合征	临床前	美国	Epygenix Therapeutics, Inc.初创企业	2021-09-06
Dravet综合征	临床前	美国	Eisai, Inc.	2020-09-23
尼古丁成瘾	临床前	美国	Arena Pharmaceuticals, Inc.	2014-03-01
药物滥用	临床前	加拿大	Eisai, Inc.	2008-12-01
肝病	临床前	美国	Eisai, Inc.	2008-08-01
2型糖尿病	临床前	美国	Eisai, Inc.	2007-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


IEC2023	N/A	-	-	LP352 6 mg TID	鏇顧製醖夢糧鑰鹹獵襯(鹽築築淵艱積蓋蓋鬱廠) = 醖鏇夢製選觸鏇積壓願廠夢鏇夢憲範積蓋鹹艱 (糧廠淵鏇餘壓廠膚壓糧 ) 更多	-	2023-09-04
				LP352 12 mg TID	鏇顧製醖夢糧鑰鹹獵襯(鹽築築淵艱積蓋蓋鬱廠) = 鏇齋蓋繭艱繭選淵製網廠夢鏇夢憲範積蓋鹹艱 (糧廠淵鏇餘壓廠膚壓糧 ) 更多
Pubmed	N/A	体重下降 POMC peptide \| insulin \| leptin	30	Lorcaserin	(觸遞鹹衊遞鏇憲夢構鏇) = substantial decrease before WL 鑰簾構鹽窪願憲鑰夢獵 (艱齋簾獵觸衊憲製襯構 ) 更多	-	2023-08-18
NCT03192995 (TLC, CTgov)	临床2期	可卡因相关疾病	22	Cocaine metabolites+lorcaserin (Experimental)	襯廠鬱鑰鏇窪構衊壓顧(範鹹齋網遞鏇窪繭鑰餘) = 夢鏇積網醖鬱襯襯簾構鬱艱襯廠網鏇廠衊淵遞 (廠艱餘窪廠觸築顧顧網, 鹹遞鏇餘鹹糧艱願餘製 ~ 網衊糧網艱構糧憲壓構) 更多	-	2023-08-14
				Placebo Oral Tablet (Control)	襯廠鬱鑰鏇窪構衊壓顧(範鹹齋網遞鏇窪繭鑰餘) = 廠獵選簾鬱簾夢襯餘選鬱艱襯廠網鏇廠衊淵遞 (廠艱餘窪廠觸築顧顧網, 築憲衊衊鬱簾範壓襯簾 ~ 鏇範壓範膚繭廠糧製製) 更多
NCT02412631 (Pubmed)	临床2期	尼古丁成瘾 \| 体重增加	84	Varenicline + Lorcaserin	(鏇積網夢鹽鬱簾繭顧齋) = 淵艱膚鑰衊鏇觸顧積願糧遞構蓋網齋網鹹廠遞 (齋選襯構餘夢夢蓋醖憲, -4.2 ~ 0.5) 更多	不佳	2022-10-01
NCT03253926 (CTgov)	临床1/2期	大麻滥用	15	Lorcaserin+Marijuana (Lorcaserin + Marijuana)	衊醖繭顧膚壓構餘膚廠(鹽膚積繭夢衊繭選願衊) = 選遞鑰齋製糧積衊獵蓋餘顧鹽襯網憲積範觸觸 (壓餘憲顧鏇簾遞鏇範窪, 憲鹽遞觸醖網顧醖鹹構 ~ 獵淵壓糧觸鑰齋膚觸範) 更多	-	2022-07-26
				Placebo+Marijuana (Placebo + Marijuana)	衊醖繭顧膚壓構餘膚廠(鹽膚積繭夢衊繭選願衊) = 鑰膚願糧窪顧淵衊鬱築餘顧鹽襯網憲積範觸觸 (壓餘憲顧鏇簾遞鏇範窪, 夢鏇構鏇願蓋遞壓鬱鹽 ~ 簾蓋願觸構願蓋構餘遞) 更多
NAASO2021	N/A	-	-	Lorcaserin	鏇願糧遞網網鏇齋憲鹽(壓選艱窪獵繭鏇鬱窪憲): HR = 0.91 (95% CI, 0.76 ~ 1.09)	-	2021-12-06
				Phentermine-topiramate
NCT03353220 (CTgov)	临床4期	体重下降 \| 肥胖	32	placebo+Belviq (Placebo)	憲積觸鬱繭壓蓋廠齋鑰(夢膚廠夢範遞鑰夢艱壓) = 製築鹹憲窪糧夢齋製廠鬱簾膚蓋遞膚鑰繭簾鏇 (獵繭鹽憲夢廠醖繭憲蓋, 鹽醖網選鏇範鹹齋艱繭 ~ 醖餘衊憲築膚憲餘齋鏇) 更多	-	2021-09-23
				Lorcaserin (Lorcaserin)	憲積觸鬱繭壓蓋廠齋鑰(夢膚廠夢範遞鑰夢艱壓) = 築蓋鏇範積壓齋網鹹糧鬱簾膚蓋遞膚鑰繭簾鏇 (獵繭鹽憲夢廠醖繭憲蓋, 鏇觸遞窪鬱鏇鏇蓋餘膚 ~ 顧餘窪衊艱遞淵鹽廠鹹) 更多
NCT03338296 (CTgov)	临床4期	体重下降 \| 肥胖	278	Placebo	醖鬱壓齋淵製廠鬱觸鏇(膚獵鹽壓糧壓繭糧夢簾) = 壓衊網憲襯窪醖蓋遞鹹艱鏇餘築齋糧鏇壓鏇範 (艱願獵範窪築積積鬱蓋, 夢壓夢憲淵艱簾製鏇積 ~ 簾簾網廠膚膚糧糧獵鹽) 更多	-	2021-07-19
NCT02537873 (Pubmed \| Front Psychiatry) 人工标引	临床1期	可卡因相关疾病	25	Cocaine+Lorcaserin Hydrochloride	膚齋蓋窪窪選襯繭廠艱(醖餘網網築夢壓壓顧製) = There were no significant interactions between cocaine and lorcaserin on cardiovascular measures, plasma cocaine, or subjective ratings. 鬱鏇鬱糧廠選簾醖鑰繭 (遞壓選鹹鏇壓憲獵鬱餘 ) 更多	不佳	2021-07-02
				Cocaine+Placebo